within Pharmacolibrary.Drugs.ATC.J;

model J02AC06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.47,
    Cl             = 0.06583333333333334,
    adminDuration  = 600,
    adminMass      = 0.6,
    adminCount     = 1,
    Vd             = 0.392,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0010166666666666666,
    Tlag           = 66.0
  );

  annotation(Documentation(
    info ="<html><body><p>Oteseconazole is a novel oral azole antifungal agent used for the treatment of recurrent vulvovaginal candidiasis. It works by inhibiting fungal CYP51 enzyme, thereby impairing ergosterol synthesis which is vital for fungal cell membrane integrity. Oteseconazole is approved for clinical use in adult women with recurrent vulvovaginal candidiasis.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult female volunteers after multiple oral dosing; manufacturer and US FDA label as primary sources.</p><h4>References</h4><ol><li><p>Ordaya, EE, et al., &amp; Vergidis, P (2023). The Role of Novel Antifungals in the Management of Candidiasis: A Clinical Perspective. <i>Mycopathologia</i> 188(6) 937–948. DOI:<a href=&quot;https://doi.org/10.1007/s11046-023-00759-5&quot;>10.1007/s11046-023-00759-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37470902/&quot;>https://pubmed.ncbi.nlm.nih.gov/37470902</a></p></li><li><p>Wiesner-Kiełczewska, A, et al., &amp; Paśko, P (2025). The Impact of Dietary Interventions on the Pharmacokinetics of Antifungal Drugs: A Systematic Review with Meta-analyses. <i>Clinical pharmacokinetics</i> None –. DOI:<a href=&quot;https://doi.org/10.1007/s40262-025-01511-6&quot;>10.1007/s40262-025-01511-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/40347349/&quot;>https://pubmed.ncbi.nlm.nih.gov/40347349</a></p></li><li><p>Sun, Y, et al., &amp; Cheng, M (2025). Design, Synthesis, and Biological Activity Evaluation of Deuterated Diphenyl Azole Alcohol-Based CYP51 Inhibitors. <i>Journal of medicinal chemistry</i> None –. DOI:<a href=&quot;https://doi.org/10.1021/acs.jmedchem.5c01068&quot;>10.1021/acs.jmedchem.5c01068</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/40461049/&quot;>https://pubmed.ncbi.nlm.nih.gov/40461049</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J02AC06;
